Evaluating the Success of Hyperthermia Treatment in Chronic Lyme Disease

— Guest Post from Michelle McKeon, MS, President, Lyme and Cancer Services

Bay Area Lyme is happy to share the editorial contributions of care providers, patients, caregivers, and others in the community who are eager to share their knowledge for the benefit of others suffering from Lyme and related tick-borne illnesses. There is still so much we don’t know and so much we are just learning. It is critical that we keep an active dialogue and share and collaborate to continue to move our understanding forward. What follows is an article written by a guest contributor and practicing care provider who shares that view and her personal and professional experience in  hopes that it can help others with their healing journeys.

***********************

Twilight zone: an area just beyond ordinary legal and ethical limits

Living with tick-borne infections is like crossing over into the twilight-zone.  Welcome to the dark side!  There is suspense.  ‘Is a significant amount of the medical community really not going to recognize Lyme as a chronic disease?!’ There is horror. ‘What? The insurance company just denied my treatment because they don’t deem it to be medically necessary?!’ And, of course, there is a psychological thriller. ‘Is this actually my life?!’

When you are at this point of your journey with late-stage Lyme, it seems as though there is no coming back.  Where does one go when they are here? Eight years ago, I asked myself this very question. At this time, hyperthermia treatment was presented as my best option. While already feeling like I was living in an alternate universe, the idea of heating up my body to above 105° F was not exactly the escape plan that I had dreamed of.  This led me to my next question…

First West Coast CME Program on Tick-borne Disease Provides New Data, Insights from Researchers

FOR IMMEDIATE RELEASE

Media Contact:
Tara DiMilia, 908-947-0500, tara.dimilia@TMstrat.com

 

First West Coast CME Program on Tick-borne Disease Provides New Data, Insights from Researchers

Stanford University School of Medicine and Massachusetts General Hospital host clinical and research forum funded by Bay Area Lyme Foundation

Silicon Valley, CA, September 3, 2019—Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., today highlights the first tick-borne disease CME program on the West Coast, Emerging Research, Diagnosis and Treatment of Lyme Disease and Tick-Borne Illness. The conference was hosted by two major academic institutions representing the East and West Coasts of the U.S., Stanford University School of Medicine and Massachusetts General Hospital, and included presentations related to the magnitude of tick-borne disease in California, emerging diagnostic technologies, potential future treatment options, and epidemiological statistics enabled by Lyme disease biobanks.

“There is a lack of understanding about the variety and severity of tick-borne illnesses such as Lyme disease on the west coast” said Charles Chiu, MD, PhD, professor of laboratory medicine and infectious diseases at UCSF, associate director of the UCSF Clinical Microbiology Laboratory, and Bay Area Lyme Foundation Scientific Advisory Board member. “This was a great opportunity to share the latest findings and ongoing research on the topic, so that physicians and other medical professionals can more quickly and accurately diagnose and treat their patients.”

Lyme Disease Biobank Expands to Increase Understanding of Lyme Disease in Heart, Brain, Joints and Other Tissues

FOR IMMEDIATE RELEASE

Media Contact:
Tara DiMilia, 908-947-0500, tara.dimilia@TMstrat.com

 

Lyme Disease Biobank Expands to Increase Understanding of Lyme Disease in Heart, Brain, Joints and Other Tissues

First-of-its-kind Biobank now accepts tissue donations from patients undergoing knee-replacements and similar surgeries, as well as patients who die with Lyme disease

Portola Valley, Calif., November 1, 2018 – Bay Area Lyme Foundation, a national organization funding research to make Lyme disease easy to diagnose and simple to cure, announces the addition of the Lyme Disease Tissue Collection Program to its Lyme Disease Biobank, which currently accepts blood samples. The expansion of the Biobank will allow for a greater understanding of the ability of Lyme bacteria to invade tissues and organs. The Lyme Disease Biobank is the only national entity working to accelerate research by collecting surgical and post-mortem tissue samples from individuals with persistent Lyme disease and other tick-borne infections.

Bay Area Lyme Foundation Sees Turning Point for Lyme Disease in 2017

FOR IMMEDIATE RELEASE

Media Contact:
Tara DiMilia, 908-947-0500, tara.dimilia@TMstrat.com

Bay Area Lyme Foundation Sees Turning Point for Lyme Disease in 2017

Organization Leaders Honored with HHS Appointment, Jane Seymour’s Open Hearts Award, Among Other Pivotal Events

PORTOLA VALLEY, Calif., December 21, 2017—Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, today announced that the organization granted $2 million in 2017 for Lyme research and education, and saw an increase of engagement from scientists, the government and noted celebrities. Studies funded by the foundation and published in 2017 provide significant support to the widely-debated scientific belief that Lyme bacteria persist after standard antibiotic treatment.  The foundation continues to demonstrate success in bringing new scientific talent to the fight against tick-borne diseases.

New Study Finds Lyme Bacteria Survive a 28-day Course of Antibiotics When Treated Four Months After Infection by Tick Bite

FOR IMMEDIATE RELEASE

Media Contact:
Tara DiMilia, 908-947-0500, tara.dimilia@TMstrat.com

New Study Finds Lyme Bacteria Survive a 28-day Course of Antibiotics When Treated Four Months After Infection by Tick Bite

All subjects treated with antibiotics were found to have some level of infection 7–12 months post treatment.Despite testing negative by antibody tests for Lyme disease, two of 10 subjects were still infected with Lyme bacteria in heart and bladder. Lyme bacteria which persist are still viable.

Portola Valley, California, Dec. 13, 2017—Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, today announced results of two papers published in the peer-reviewed journals PLOS ONE and American Journal of Pathology, that seem to support claims of lingering symptoms reported by many patients who have already received antibiotic treatment for the disease.

Bay Area Lyme Foundation Now Accepting Applications for $450,000 in Emerging Leader Award Research Grants

FOR IMMEDIATE RELEASE

Media Contact:
Tara DiMilia, 908-947-0500, tara.dimilia@TMstrat.com

Bay Area Lyme Foundation Now Accepting Applications for $450,000 in Emerging Leader Award Research Grants

‘Emerging Leader Award’ aims to attract new scientific talent to address challenges of Lyme disease

Portola Valley, California, December 5, 2017—Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, today announced a call for applications for three Bay Area Lyme Foundation ‘Emerging Leader Award’ grants, one for $250,000 and the other two for $100,000. These awards will be given to promising scientists who embody the future of leadership in Lyme disease research in the US. The award recipients will be researchers in academia or the private sector who have demonstrated professional and scientific leadership in the biomedical sciences and who can offer scientific rationale for a research project that can advance diagnostics or treatments for Lyme disease.

Why Is Lyme Disease Not Covered by Insurance?

by Daniel Lynch, Founder & President, Medical Bill Gurus

This week, we have a guest post from Daniel Lynch. Daniel Lynch is the founder of Medical Bill Gurus, a patient and physician advocacy company that specializes in navigating the complex issues associated with healthcare and medical bills. His mission, he explains is to “utilize our wealth of information to ‘pay it forward’ to those who need assistance! … Although most claims for Lyme disease are typically at cash-only medical providers and not covered by insurance companies, we at Medical Bill Gurus have put together a process of breaking down bills, and identifying components of treatment that are covered by PPO insurance plans.”

Here he shares his perspective and some tips. Bay Area Lyme Foundation has no connection with Medical Bill Gurus and this post is not an endorsement of their services. At Bay Area Lyme, we are committed to supporting the community by ensuring access to information and resources to help them deal with Lyme disease.

CRISPR Technology: A New Approach to Eradicating Borrelia

courtesy Beisel Lab, NCSUDr. Chase Beisel is an Assistant Professor at North Carolina State University who was recognized earlier this year with one of Bay Area Lyme Foundation’s prestigious Emerging Leader Awards. This honor is in recognition of and support for his lab‘s novel work exploring CRISPR technology as a potential treatment for Lyme infections.

Dr. Beisel’s work integrates molecular biology, chemical engineering, and mathematical modeling and has been acknowledged with several National Science Foundation (NSF),  National Institute for Health (NIH) and other important awards. His foray into the field of Lyme is a new direction for his lab and ties directly to the Foundation’s aim of attracting some of the brightest and best minds in the country to apply innovative new approaches and methodology to accelerate the development of new diagnostics and treatments for Lyme disease. We are excited about his work and asked him to elaborate further in this recent conversation.

California Strains of Lyme Bacteria May Survive Antibiotic Treatment, According to New Study

FOR IMMEDIATE RELEASE

Media Contact:
Tara DiMilia, 908-947-0500, tara.dimilia@TMstrat.com

California Strains of Lyme Bacteria May Survive Antibiotic Treatment, According to New Study

This new study funded by Bay Area Lyme Foundation identifies 20 FDA-approved compounds that are more effective in inhibiting persistent Lyme bacteria than standard treatment

Silicon Valley, CA, April 6, 2016—A laboratory study published today, funded by the Bay Area Lyme Foundation, is the first study to demonstrate that strains of Lyme bacteria present in California ticks are able to form persister bacteria, which do not respond well to treatment.  The study is also the first to identify FDA-approved therapies that may be more effective in inhibiting these specific strains of persister bacteria in the lab than doxycycline, the most commonly prescribed treatment for Lyme disease. The study was conducted by Stanford School of Medicine researchers and published in the Open Access publication Drug Design, Development and Therapy. View full study here: http://www.dovepress.com/articles.php?article_id=26319

Can We “Hack” Our Way to Some New Solutions for Lyme?

Reflections from a Promising Dialogue at the AAAS Conference in Washington, DC, November 17-18

by Lia Gaertner, BAL Science Committee

AAAS_Logo and magSome weeks ago, two members of the Bay Area Lyme Foundation Science Committee, Wendy Adams and Lia Gaertner, attended a leadership symposium in Washington, DC, sponsored by the American Association for the Advancement of Science (AAAS) and entitled, “Innovations-X: Rising Above the Politics for Progress in Science.”  The AAAS is the world’s largest general scientific society, with more than 125,000 individual and institutional members, and the publisher of Science magazine. Its mission is “to advance science, engineering, and innovation throughout the world for the benefit of all people.” At this event, there were three “wicked problems” discussed over two days: climate change, global/mobile health, and Lyme disease.  This blog, written by Lia Gaertner, will focus only on the Lyme portion of the conference.